



Alnylam Pharmaceuticals, Inc.  
Investor Relations Department  
300 Third Street  
Cambridge, MA 02142  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: ALNY <sup>1</sup>

Last Trade:	85.21
Trade Time:	4:00 PM ET 06.23.2017
Change:	1.25  (1.489%)
Day Range	82.13 - 85.33
52-Week Range	31.38 - 86.92
Volume	773,700
Market Cap. (\$M)	7,795.863
Shares Out (M)	91.490

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Alnylam 5x15™" product strategy. Alnylam's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 06.19.2017  
[Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term](#)
- 06.12.2017  
[Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office](#)
- 06.07.2017  
[Alnylam Expands Third Annual "Helping Hands" Community Service Day Globally to Benefit 18 Organizations](#)
- 05.31.2017  
[FDA Grants Breakthrough Therapy Designation for Alnylam's Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria](#)
- 05.30.2017  
[Alnylam to Webcast Presentation at Jefferies 2017 Healthcare Conference](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [First Quarter Financial Results](#)

- 02.15.2017  
[Annual Report \(10-K\)](#)
- 03.17.2017  
[Definitive Proxy Statement](#)
- 05.05.2017  
[Quarterly Report \(10-Q\)](#)
- 11.03.2016  
[Quarterly Report \(10-Q\)](#)
- 08.04.2016  
[Quarterly Report \(10-Q\)](#)